On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human.
With the combined pharmacokinetic-pharmacodynamic approach, the bioavailability and venoconstrictor effects of two DHE formulations (programmed release capsules and oral solution) have been compared after acute oral dose administrations in the healthy volunteer subjects. The bioavailability of DHE from programmed release capsules has been significantly greater than that shown by the oral solution. DHE capsules formulation has seemed to provide appropriate plasma concentrations for at least 10 h after administration. That may well account for its efficacy in the treatment of morning migraine.
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D055598:Chemical Phenomena; D002621:Chemistry; D003692:Delayed-Action Preparations; D004087:Dihydroergotamine / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D004087:Dihydroergotamine